Addressing Opioid Overdose and Opioid Use Disorder: Medication-Based Treatment Approaches

Alexander Y. Walley, MD, MSc
Associate Professor of Medicine, BUSM
Director, Addiction Medicine Fellowship, BMC
Medical Director, Opioid Overdose Prevention Pilot Program, MDPH

MAT Commission
Thursday, January 24, 2019
Objectives

Review how medication for opioid use disorder (MOUD) works
Review outcomes
Opportunities for delivering MOUD to high risk patient populations
Why do people use opioids?

- To feel good
- To feel better

Withdrawal

- Acute use
- Chronic use

Tolerance and Physical Dependence
## Goals of medication for opioid use disorder

<table>
<thead>
<tr>
<th>Category</th>
<th>Medication Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relief of withdrawal symptoms</td>
<td>Low dose methadone (30-40mg), buprenorphine</td>
</tr>
<tr>
<td>Opioid blockade</td>
<td>High dose methadone (&gt;60mg), buprenorphine, naltrexone</td>
</tr>
<tr>
<td>Reduce opioid craving</td>
<td>High dose methadone (&gt;60mg), buprenorphine, naltrexone</td>
</tr>
<tr>
<td>Restoration of reward pathway</td>
<td>Long term (&gt;6 months)</td>
</tr>
<tr>
<td></td>
<td>methadone, buprenorphine, naltrexone</td>
</tr>
</tbody>
</table>
Matching Patients to Medications for Opioid Use Disorder

• The choice of methadone, buprenorphine, or naltrexone depends upon:
  • Patient preference
  • Past experience
  • Likelihood of continuing the treatment
  • Access to treatment setting
  • Ability to manage withdrawal (esp for naltrexone)
## Matching Patients to Medications for OUD

<table>
<thead>
<tr>
<th>Medication</th>
<th>Abstinence required?</th>
<th>Dosing schedule</th>
<th>Required Training - Regulation</th>
<th>Retention</th>
<th>Reduce Illicit Opioid Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable IM Naltrexone</td>
<td>7-10 days</td>
<td>Q28 day provider injection</td>
<td>None</td>
<td>Good - trial Poor - real-world</td>
<td>Excellent</td>
</tr>
<tr>
<td>Oral Naltrexone</td>
<td>7-10 days</td>
<td>Daily prescription</td>
<td>None</td>
<td>No better than placebo</td>
<td>Limited due to non-adherence</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>12 hours(^1)</td>
<td>Daily prescription</td>
<td>8 hr MD/DO 24 hr NP/PA</td>
<td>Not as good as methadone</td>
<td>Excellent</td>
</tr>
<tr>
<td>Methadone</td>
<td>No, BUT start low go slow</td>
<td>Daily clinic administered(^2)</td>
<td>Licensed clinic only</td>
<td>Best</td>
<td>Excellent</td>
</tr>
</tbody>
</table>

\(^1\) 24-72 hours of abstinence needed when switching from methadone to buprenorphine  
\(^2\) Take homes can be earned after 60 days
Maintenance Treatment for Severe Opioid Use Disorder

- **Withdrawal**
  - Chronic use
  - Maintenance

- **Euphoria**

- **Start naltrexone**

- 7-10 days
Naltrexone

• Pure opioid antagonist

• Injectable naltrexone (Vivitrol®)
  • Monthly IM injection
  • FDA approved 2010
  • Patients must be opioid free for a minimum of 7-10 days before treatment

• Oral naltrexone
  • Duration of action 24-48 hours
  • FDA approved 1984
  • 2008 Cochrane Review
    • No clear benefit in treatment retention or relapse at follow up over placebo
    • Physicians > 80% abstinence at 18 months

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>NTX</th>
<th>placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial completion</td>
<td>53%</td>
<td>38%</td>
</tr>
<tr>
<td>Abstinence at 24 weeks</td>
<td>90%</td>
<td>35%</td>
</tr>
<tr>
<td>Change in craving score</td>
<td>-10.1</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Maintenance Treatment for Severe Opioid Use Disorder

Withdrawal

Normal

Chronic use

Start buprenorphine

12hr

Maintenance
How does buprenorphine work?

- High affinity, but low activity at the mu opioid receptor
  - Low activity is enough activity to TREAT WITHDRAWAL and REDUCE CRAVINGS
  - Low activity results in a CEILING EFFECT
    - Euphoria is unusual
    - Overdose occurs only with other drugs of abuse
    - Opioid dependent patients FEEL NORMAL
  - High affinity means it is a BLOCKER, more active opioids can not stimulate the receptor in presence of buprenorphine
How do buprenorphine + naloxone work?

• Buprenorphine has good sublingual and IV bioavailability but poor GI bioavailability
• Naloxone (Narcan) has good IV bioavailability, but poor GI and sublingual bioavailability
• The combination results in decreased abuse and diversion for IV use
Methadone Maintenance Treatment
Highly Structured

• Daily nursing assessment
• Weekly individual and/or group counseling
• Random supervised toxicology screens
• Medical director oversight
• Methadone dosing
  • Observed daily ⇒ “Take homes”

- Separate system not involving primary care
- Limited access
  • 5 states: 0 clinics
  • 4 states: < 3 clinics
- Inconvenient and highly punitive
- Mixes stable and unstable patients
- Lack of privacy
- No ability to “graduate”
- Stigma
Opioid Detox Outcomes

- Low rate of retention in treatment
- High rates of relapse post treatment
  - < 50% abstinent at 6 months
  - < 15% abstinent at 12 months
  - Increased rates of overdose due to decreased tolerance

So, how long should maintenance treatment last?

Long enough

O’Connor PG JAMA 2005
Mattick RP, Hall WD. Lancet 1996
Stimmel B et al. JAMA 1977
Medication saves lives. People die when medication stops.

4.4% (~300K) of Massachusetts adults have opioid use disorder in 2015
- Using capture-recapture methods of 7-linked datasets with 45+% known

National survey estimate of OUD prevalence is **0.6% = 2.1 million / 326 million adults in 2016**
- newsletter.samhsa.gov/2017/10/12/samhsa-new-data-mental-health-substance-use-including-opioids/
Major variation across states and payers
- Diagnosed prevalence of opioid use disorder by state and payer, 2015 (or most recent year)

FIGURE 6: DIAGNOSED PREVALENCE OF OPIOID USE DISORDER BY STATE AND PAYER, 2015 (OR MOST RECENT YEAR)
**Touchpoint:**
A health care, public health, or criminal justice encounter were we can:

- identify individuals at high-risk for opioid overdose death
- deliver overdose risk reduction services, and/or
- link and engage in treatment

Examples: Post-overdose, while incarcerated, when hospitalized, residential treatment, if civilly committed

- We are missing opportunities to engage people
- When people are treated with MOUD, their mortality is cut in half or more
- When people discontinue treatment, they die
  -> We need to make the treatment work for the patient
  .....not make the patient work for the treatment
Looking back...
Population attributable fraction for touchpoints prior to opioid overdose death (Massachusetts, 2014, n=1,315 opioid-related deaths)

Source: Larochelle et al, SGIM 2018, Data from Chapter 55 Data Set
Making the treatment work for the patient
- Initiating medication at venues for high risk patients

Buprenorphine RCT for medical inpatients with OUD

- Linked to outpatient care: 72% vs. 12%
- Remained on bup at 6 months: 17% vs. 3.0%
- Median days of illicit opioid use in last 30 days at 6 months: 4.0 vs. 13.9 days

Buprenorphine RCT for emergency patients with OUD

- Linked to outpatient care: 78% vs. 37%
- Reduction in use day per week: 4.5 vs. 3.1
- Admitted to inpatient treatment: 11% vs. 37%

After overdose, few survivors receive medications for OUD
Cohort of 17,755 overdose survivors in MA, 2012-2014

After overdose, few survivors receive medications for OUD
Cohort of 17,755 overdose survivors in MA, 2012-2014

<table>
<thead>
<tr>
<th>Medication</th>
<th>% Receiving Medication</th>
<th>Months Received (median [IQR])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any MOUD</td>
<td>30%</td>
<td></td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>17% 4 [2,8]</td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td>12% 5 [2,9]</td>
<td></td>
</tr>
<tr>
<td>Naltrexone</td>
<td>6% 1 [1,2]</td>
<td></td>
</tr>
</tbody>
</table>

Overdose survivors who receive medications have better survival
Cohort of 17,755 overdose survivors in MA, 2012-2014

Overdose survivors who receive medications have better survival

Cohort of 17,755 overdose survivors in MA, 2012-2014

Cost Savings of Treatment

• **Methadone** maintenance patients health care costs 50%-62% lower than those not on MMT

• Adherence to **buprenorphine** has higher pharmacy, but lower outpatient, inpatient, ED, and total healthcare costs ($28K vs. $49K)

MOUD Access Innovations

- Opt out, instead of opt in
  - Convert “detox” into induction sites
  - Hospital/ED patients, especially post-OD
  - MOUD in jails/prisons
  - MOUD through pharmacies
- More evidence-based MOUD choices
  - 24-hour oral morphine
  - Injectable opioid agonist treatment – heroin and hydromorphone
Realistic Expectations!

Addiction is a chronic relapsing condition

Over time treatment works
People get better

Thank you!
awalley@bu.edu
Treatment has not kept pace with incidence

2010-14 claims database of >200 million commercially insured in US

- 4-fold-increase in OUD dx
  - 0.12% → 0.48%
- BUT, proportion treated decreased
  - 25% → 16%

Treatment has not kept pace with incidence

- Discontinuation is common, especially with naltrexone